Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.
复制标题
DOI：
10.1093/ofid/ofab353
复制
发表时间：
2021-07
影响因子：
4.2
通讯作者：
Haidar G
中科院分区：
文献类型：
--
作者：
Agha ME;Blake M;Chilleo C;Wells A;Haidar G
我们测定了67例血液系统恶性肿瘤患者接种2剂信使RNA疫苗后对严重急性呼吸综合征冠状病毒2型免疫球蛋白G的反应。46%为无应答者; B细胞慢性淋巴细胞白血病患者风险最高（77%无应答者）。恶性血液病患者应继续佩戴口罩，保持社交距离。需要研究再接种疫苗、加强剂和体液免疫相关的保护作用。
We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders). Patients with hematological malignancies should continue wearing masks and socially distancing. Studies of revaccination, boosters, and humoral immune correlates of protection are needed.